Cure My Disease

Don't miss your cure!

 Log in / Sign up

New hope for kids with stubborn bedwetting: drug combo shows promise

NCT ID NCT07398261

Symptom relief Sponsor: Menoufia University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether a drug called mirabegron, alone or combined with desmopressin, can help children who wet the bed and also have daytime bladder issues. About 151 children will take part. The goal is to see if the treatment reduces or stops nighttime accidents.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

About 151 people

The number the study aims to enrol. It can still change while the study runs.

Started

Aug 2023

Expected to finish

Nov 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

Children (under 18), adults (18 to 64) and older adults (65 and over)

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: \- Non-monosymptomatic nocturnal enuresis Exclusion Criteria: * monosymptomatic nocturnal enuresis

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Treatment of non-monosymptomatic nocturnal enuresis are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

nocturnal enuresis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Treatment of non-monosymptomatic nocturnal enuresis

Contacts and locations

Locations

  • Menoufia faculty of medicine

    Shibīn al Kawm, Monufia Governorate, 32616, Egypt